Gavilimomab

Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.^[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.^[2]

Gavilimomab

Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CD147
Clinical data
ATC code	none
Identifiers
CAS Number	244096-20-6 N
ChemSpider	none
UNII	TCR92293RC
NY (what is this?)  (verify)

It was originally developed by Abgenix,^[1] which was later acquired by Amgen.

References

1. "Gavilimomab". Adis Insight. Springer Nature Switzerland AG.
2. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, et al. (March 2007). "A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease". Blood. 109 (6): 2657–62. doi:10.1182/blood-2006-08-013995. PMID 17110457.